AQR Capital Management
CPRX icon

AQR Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

AQR Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.65M Sell
228,351
-75,300
-25% -$1.79M ﹤0.01% 1674
2025
Q4 		$7.09M Sell
303,651
-33,401
-10% -$744K ﹤0.01% 1374
2025
Q3 		$6.64M Sell
337,052
-61,370
-15% -$1.26M ﹤0.01% 1288
2025
Q2 		$8.65M Sell
398,422
-47,088
-11% -$1.11M 0.01% 1027
2025
Q1 		$10.8M Sell
445,510
-31,501
-7% -$709K 0.01% 851
2024
Q4 		$9.96M Buy
477,011
+17,659
+4% +$379K 0.01% 827
2024
Q3 		$9.13M Sell
459,352
-29,034
-6% -$538K 0.01% 831
2024
Q2 		$7.57M Buy
488,386
+227,321
+87% +$3.54M 0.01% 849
2024
Q1 		$4.16M Sell
261,065
-81,736
-24% -$1.23M 0.01% 1060
2023
Q4 		$5.76M Sell
342,801
-133,999
-28% -$1.83M 0.01% 889
2023
Q3 		$5.57M Sell
476,800
-166,194
-26% -$2.22M 0.01% 872
2023
Q2 		$8.64M Buy
642,994
+378,770
+143% +$5.45M 0.02% 706
2023
Q1 		$4.38M Buy
264,224
+35,794
+16% +$591K 0.01% 951
2022
Q4 		$4.25M Sell
228,430
-172,201
-43% -$2.65M 0.01% 971
2022
Q3 		$5.14M Sell
400,631
-86,910
-18% -$1.03M 0.01% 829
2022
Q2 		$3.42M Buy
487,541
+73,989
+18% +$543K 0.01% 909
2022
Q1 		$3.43M Sell
413,552
-24,521
-6% -$173K 0.01% 947
2021
Q4 		$2.97M Sell
438,073
-37,244
-8% -$245K 0.01% 980
2021
Q3 		$2.52M Buy
475,317
+151,119
+47% +$826K ﹤0.01% 1029
2021
Q2 		$1.86M Sell
324,198
-399,455
-55% -$2.06M ﹤0.01% 1251
2021
Q1 		$3.34M Sell
723,653
-269,778
-27% -$1.07M 0.01% 951
2020
Q4 		$3.32M Buy
993,431
+143,899
+17% +$483K 0.01% 923
2020
Q3 		$2.52M Sell
849,532
-55,712
-6% -$218K ﹤0.01% 1004
2020
Q2 		$4.18M Sell
905,244
-307,205
-25% -$1.38M 0.01% 857
2020
Q1 		$4.67M Buy
1,212,449
+77,305
+7% +$317K 0.01% 809
2019
Q4 		$4.26M Buy
1,135,144
+968,574
+581% +$4.53M ﹤0.01% 1017
2019
Q3 		$884K Sell
166,570
-113,868
-41% -$607K ﹤0.01% 1564
2019
Q2 		$1.08M Buy
280,438
+217,841
+348% +$941K ﹤0.01% 1469
2019
Q1 		$319K Sell
62,597
-77,245
-55% -$227K ﹤0.01% 1952
2018
Q4 		$268K Sell
139,842
-58,754
-30% -$168K ﹤0.01% 1995
2018
Q3 		$751K Sell
198,596
-176,800
-47% -$554K ﹤0.01% 1814
2018
Q2 		$1.17M Sell
375,396
-427,301
-53% -$1.3M ﹤0.01% 1648
2018
Q1 		$1.92M Buy
802,697
+466,119
+138% +$1.55M ﹤0.01% 1375
2017
Q4 		$1.32M Sell
336,578
-16,048
-5% -$53K ﹤0.01% 1563
2017
Q3 		$889K Buy
+352,626
New +$967K ﹤0.01% 1715
2016
Q1 		– Sell
-63,742
Closed -$156K – 2229
2015
Q4 		$156K Sell
63,742
-75,820
-54% -$217K ﹤0.01% 2183
2015
Q3 		$419K Sell
139,562
-45,220
-24% -$195K ﹤0.01% 1794
2015
Q2 		$763K Hold
184,782
– – ﹤0.01% 1626
2015
Q1 		$800K Sell
184,782
-26,100
-12% -$94.1K ﹤0.01% 1511
2014
Q4 		$626K Sell
210,882
-29,400
-12% -$80.7K ﹤0.01% 1864
2014
Q3 		$798K Hold
240,282
– – ﹤0.01% 1728
2014
Q2 		$608K Buy
240,282
+39,000
+19% +$83.3K ﹤0.01% 1901
2014
Q1 		$455K Buy
201,282
+51,600
+34% +$108K ﹤0.01% 2089
2013
Q4 		$292K Buy
+149,682
New +$303K ﹤0.01% 2309

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management's CPRX Position: Q1 2026 in Review

AQR Capital Management reduced its Catalyst Pharmaceutical (CPRX) stake by 25% in Q1 2026, selling an estimated $1.79M and leaving 228,351 shares worth $5.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1674.

AQR Capital Management first reported a position in CPRX in Q4 2013 and has held it in 44 quarters since. The position peaked at $10.8M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • AQR Capital Management held 228,351 shares of Catalyst Pharmaceutical worth $5.65M as of Q1 2026.
  • AQR Capital Management sold 75,300 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.79M.
  • Catalyst Pharmaceutical made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1674 holding.
  • AQR Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2013 and has held it in 44 quarters since.
  • AQR Capital Management's Catalyst Pharmaceutical position peaked at $10.8M in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.